SCHEMBL5569110

SCHEMBL5569110

Cc1cc(Cl)ccc1Nc1ncnc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.60
FADS1 O60427 1/20 0.60
LCK P06239 1/20 0.59
MAPK1 P28482 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 1/20 0.52
HTT P42858 2/20 0.52
HIF1A Q16665 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
DAPK3 O43293 1/20 0.51
MAP4K4 O95819 1/20 0.51
ABL1 P00519 1/20 0.51
ERBB2 P04626 1/20 0.51
PIM1 P11309 1/20 0.51
PRKACA P17612 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568040 0.89 EGFR (0.60) EGFRFADS1LCKMAPK1SMN1; SMN2
SCHEMBL9017030 0.89 SRC (0.55) EGFRSMN1; SMN2ALDH1A1HPGDHTT
Hydrochloric Acid SCHEMBL9017039 0.87 SRC (0.54) EGFRLCKSMN1; SMN2HTTAURKB
SCHEMBL14050059 0.86 KDR (0.64) EGFRMAPK1SMN1; SMN2ALDH1A1HPGD
SCHEMBL5568397 0.86 EGFR (0.68) EGFRFADS1LCKMAPK1SMN1; SMN2
SCHEMBL5569191 0.83 GAA (0.65) EGFRMAPK1SMN1; SMN2ALDH1A1HPGD
SCHEMBL11082678 0.83 RXFP1 (0.63) EGFRFADS1LCKSMN1; SMN2ALDH1A1
SCHEMBL8907064 0.83 EGFR (0.60) EGFRFADS1MAPK1SMN1; SMN2ALDH1A1
SCHEMBL5564798 0.83 EGFR (0.60) EGFRFADS1LCKMAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL11085544 0.82 RXFP1 (0.62) EGFRFADS1LCKSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT EGFR 1445/4885FADS1 4484/4885LCK 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.